{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:44:37Z","timestamp":1794113077109,"version":"4.8.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.parkreldis.2023.105488","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T17:38:55Z","timestamp":1687369135000},"page":"105488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Neuroimaging biomarkers in Huntington's disease: Preparing for a new era of therapeutic development"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6951-2325","authenticated-orcid":false,"given":"Thilo","family":"van Eimeren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0092-5164","authenticated-orcid":false,"given":"Kathrin","family":"Giehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Reetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.parkreldis.2023.105488_bib1","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey","year":"2013","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2023.105488_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105488_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.GIM.0000106165.74751.15","article-title":"Technical standards and guidelines for Huntington disease testing","volume":"6","author":"Potter","year":"2004","journal-title":"Genet. Med."},{"key":"10.1016\/j.parkreldis.2023.105488_bib4","series-title":"Huntington's Disease Integrated Staging System (HD-ISS): A Novel Evidence-Based Classification System for Staging, medRxiv Preprint","author":"Tabrizi","year":"2021"},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105488_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mdc3.12571","article-title":"Rating scales for motor symptoms and signs in huntington's disease: critique and recommendations","volume":"5","author":"Mestre","year":"2017","journal-title":"Mov. Disord .Clin. Pract."},{"key":"10.1016\/j.parkreldis.2023.105488_bib8","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.parkreldis.2023.105488_bib9","series-title":"Computation of Effect Sizes","year":"2020"},{"key":"10.1016\/j.parkreldis.2023.105488_bib10","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"6.5.2.2 Obtaining standard deviations from standard errors and confidence intervals for group means","author":"Higgins","year":"2021"},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105488_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.22237\/jmasm\/1257035100","article-title":"New effect size rules of thumb","volume":"8","author":"Sawilowsky","year":"2009","journal-title":"J. Mod. Appl. Stat. Methods"},{"issue":"Pt 5","key":"10.1016\/j.parkreldis.2023.105488_bib12","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study","volume":"126","author":"Pavese","year":"2003","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105488_bib13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1468-1331.2008.02390.x","article-title":"Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease","volume":"16","author":"Van Oostrom","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"Pt 11","key":"10.1016\/j.parkreldis.2023.105488_bib14","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awm217","article-title":"Thalamic metabolism and symptom onset in preclinical Huntington's disease","volume":"130","author":"Feigin","year":"2007","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.parkreldis.2023.105488_bib15","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1172\/JCI69411","article-title":"Metabolic network as a progression biomarker of premanifest Huntington's disease","volume":"123","author":"Tang","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.parkreldis.2023.105488_bib16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00415-014-7350-7","article-title":"Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease","volume":"261","author":"Herben-Dekker","year":"2014","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.parkreldis.2023.105488_bib17","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-009-1103-3","article-title":"Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins","volume":"36","author":"Squitieri","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"issue":"7","key":"10.1016\/j.parkreldis.2023.105488_bib18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/mds.22969","article-title":"Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease","volume":"25","author":"Wild","year":"2010","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105488_bib19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2023.105488_bib20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.22485","article-title":"Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease","volume":"24","author":"Henley","year":"2009","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.parkreldis.2023.105488_bib21","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/1531-8257(200005)15:3<552::AID-MDS1020>3.0.CO;2-P","article-title":"Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease","volume":"15","author":"Aylward","year":"2000","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105488_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JHD-130076","article-title":"Regional atrophy associated with cognitive and motor function in prodromal Huntington disease","volume":"2","author":"Aylward","year":"2013","journal-title":"J. Huntingtons Dis."},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105488_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","article-title":"Longitudinal change in regional brain volumes in prodromal Huntington disease","volume":"82","author":"Aylward","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.parkreldis.2023.105488_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074131","article-title":"Multi-modal neuroimaging in premanifest and early Huntington's disease: 18 month longitudinal data from the IMAGE-HD study","volume":"8","author":"Dominguez","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.parkreldis.2023.105488_bib25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1192\/bjp.bp.114.156588","article-title":"Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data","volume":"208","author":"Dom\u00ednguez","year":"2018","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.parkreldis.2023.105488_bib26","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3174\/ajnr.A2018","article-title":"Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study","volume":"31","author":"Hobbs","year":"2010","journal-title":"Am. J. Neuroradiol."},{"issue":"14","key":"10.1016\/j.parkreldis.2023.105488_bib27","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/mds.23912","article-title":"Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation","volume":"26","author":"Majid","year":"2011","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105488_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.parkreldis.2023.105488_bib29","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1474-4422(14)70238-8","article-title":"Coordinators of the Huntington Study, Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study","volume":"13","author":"Paulsen","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105488_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JHD-170236","article-title":"Dynamic prediction of motor diagnosis in huntington's disease using a Joint modeling approach","volume":"6","author":"Li","year":"2017","journal-title":"J. Huntingtons Dis."},{"issue":"5","key":"10.1016\/j.parkreldis.2023.105488_bib31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/jcbfm.1989.98","article-title":"Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis","volume":"9","author":"Farde","year":"1989","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"Pt 6","key":"10.1016\/j.parkreldis.2023.105488_bib32","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.parkreldis.2023.105488_bib33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1192\/bjp.bp.114.156588","article-title":"Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data","volume":"208","author":"Dominguez","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.parkreldis.2023.105488_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.712555","article-title":"Volumetric MRI-based biomarkers in huntington's disease: an evidentiary review","volume":"12","author":"Kinnunen","year":"2021","journal-title":"Front. Neurol."},{"issue":"3\u20134","key":"10.1016\/j.parkreldis.2023.105488_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.brainresbull.2010.04.003","article-title":"Striatal and white matter predictors of estimated diagnosis for Huntington disease","volume":"82","author":"Paulsen","year":"2010","journal-title":"Brain Res. Bull."},{"issue":"8","key":"10.1016\/j.parkreldis.2023.105488_bib36","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington's disease decades before diagnosis: the Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.parkreldis.2023.105488_bib37","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/mds.22601","article-title":"Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study","volume":"24","author":"Biglan","year":"2009","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105488_bib38","first-page":"215","article-title":"Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease","volume":"47","author":"Ciarmiello","year":"2006","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105488_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.expneurol.2008.12.026","article-title":"Longitudinal diffusion tensor imaging in Huntington's Disease","volume":"216","author":"Weaver","year":"2009","journal-title":"Exp. Neurol."},{"issue":"Pt 12","key":"10.1016\/j.parkreldis.2023.105488_bib40","first-page":"2353","article-title":"Huntington's disease progression","volume":"122","author":"Andrews","year":"1999","journal-title":"PET Clin. Observat.Brain"},{"key":"10.1016\/j.parkreldis.2023.105488_bib41","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/122.9.1667","article-title":"Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease","volume":"122","author":"Harris","year":"1999","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.parkreldis.2023.105488_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.brainresbull.2003.09.005","article-title":"Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study","volume":"62","author":"Aylward","year":"2003","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105488_bib43","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/01.WNL.0000132965.14653.D1","article-title":"Onset and rate of striatal atrophy in preclinical Huntington disease","volume":"63","author":"Aylward","year":"2004","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.parkreldis.2023.105488_bib44","first-page":"1715","article-title":"fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease","volume":"25","author":"Paulsen","year":"2004","journal-title":"Ajnr Am. J.Neuroradiol."},{"issue":"11","key":"10.1016\/j.parkreldis.2023.105488_bib45","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/brain\/awn212","article-title":"Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease","volume":"131","author":"Leoni","year":"2008","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105488_bib46","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.neuroimage.2009.06.003","article-title":"Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington's disease","volume":"47","author":"Hobbs","year":"2009","journal-title":"Neuroimage"},{"issue":"7","key":"10.1016\/j.parkreldis.2023.105488_bib47","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/jnnp.2009.190702","article-title":"The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study","volume":"81","author":"Hobbs","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.parkreldis.2023.105488_bib48","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.nbd.2010.07.014","article-title":"Cerebral cortex structure in prodromal Huntington disease","volume":"40","author":"Nopoulos","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"9","key":"10.1016\/j.parkreldis.2023.105488_bib49","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/mds.23762","article-title":"A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study","volume":"26","author":"Rosas","year":"2011","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2023.105488_bib50","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.parkreldis.2023.105488_bib51","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cortex.2013.11.009","article-title":"White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression","volume":"52","author":"Novak","year":"2014","journal-title":"Cortex"},{"issue":"9","key":"10.1016\/j.parkreldis.2023.105488_bib52","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.biopsych.2011.07.030","article-title":"Striatal volume contributes to the prediction of onset of Huntington disease in incident cases","volume":"71","author":"Aylward","year":"2012","journal-title":"Biol. Psychiatr."},{"issue":"5","key":"10.1016\/j.parkreldis.2023.105488_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/acn3.558","article-title":"An image-based model of brain volume biomarker changes in Huntington's disease","volume":"5","author":"Wijeratne","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.parkreldis.2023.105488_bib54","article-title":"Whole-brain segmentation and change-point analysis of anatomical brain MRI-application in premanifest huntington's disease","volume":"136","author":"Wu","year":"2018","journal-title":"J. Vis. Exp."},{"issue":"4","key":"10.1016\/j.parkreldis.2023.105488_bib55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jnr.24358","article-title":"Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI","volume":"97","author":"Chen","year":"2019","journal-title":"J. Neurosci. Res."},{"issue":"5","key":"10.1016\/j.parkreldis.2023.105488_bib56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3174\/ajnr.A4617","article-title":"Quantitative susceptibility mapping suggests altered brain iron in premanifest Huntington disease","volume":"37","author":"van Bergen","year":"2016","journal-title":"AJNR Am. J.Neuroradiol."},{"key":"10.1016\/j.parkreldis.2023.105488_bib57","series-title":"Brain MRI Volume Changes after 12 Months Laquinimod Treatment of Huntington Disease (LEGATO-HD)","author":"Reilmann","year":"2019"},{"issue":"1","key":"10.1016\/j.parkreldis.2023.105488_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97334-z","article-title":"Pharmacological characterization of mutant huntingtin aggregate-directed PET imaging tracer candidates","volume":"11","author":"Herrmann","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parkreldis.2023.105488_bib59","article-title":"Longitudinal preclinical evaluation of the novel radioligand [11C]CHDI-626 for PET imaging of mutant huntingtin aggregates in Huntington's disease","author":"Bertoglio","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.parkreldis.2023.105488_bib60","series-title":"FuRST 2.0 Cognitive Pre-testing","year":"2021"},{"key":"10.1016\/j.parkreldis.2023.105488_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.595679","article-title":"Utility of huntington's disease assessments by disease stage: floor\/ceiling effects","volume":"12","author":"Abreu","year":"2021","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.parkreldis.2023.105488_bib62","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for alzheimer disease-the FDA's perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.parkreldis.2023.105488_bib63","first-page":"301","article-title":"Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a Neuroimaging Biomarker Utility System","volume":"11","author":"van Eimeren","year":"2019","journal-title":"Alzheim. Dement"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802023002110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802023002110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:28:38Z","timestamp":1761179318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802023002110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":61,"alternative-id":["S1353802023002110"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105488","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroimaging biomarkers in Huntington's disease: Preparing for a new era of therapeutic development","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105488"}}